Vaxcyte Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon, everybody. Welcome to Guggenheim's Healthcare Innovation Conference. I am Seamus Fernandez, one of the Senior Biopharma Analysts here at Guggenheim, and I am really pleased to be joined again this year by the Vaxcyte team. Not necessarily spelled the same, sounds an awful lot like the namesake, but Andrew Guggenhime is immediately to my right, President and CFO. Jim Wassil, to his right, EVP, COO, and CSO. Mike Mullette, the Chief Commercial Officer. Maybe we will just kind of kick off. Let's talk about the VAX-31 adult program just as a starting point. Actually, Andrew, I did want you to jump in, maybe provide some introductory thoughts on the state of the business before we get right there, and just the vaccines market in general as you see it.
Great. First of all, thanks, Seamus, to you and to your colleagues at Guggenheim for the opportunity to be here at the conference to present today. Great to be here. This is a very exciting time for Vaxcyte. For those of you that are less familiar with the company, we are exclusively focused on developing and commercializing novel vaccines to prevent or treat bacterial infectious diseases. We have a proprietary technology platform that allows us to make and develop vaccines to address some of the limitations that the conventional technologies face, and we are leveraging that proprietary technology across our pipeline of vaccines, led by our pneumococcal conjugate vaccine, or PCV franchise. Seamus, you asked about VAX-31. This is an $8.5 billion global market comprised $2.5 billion-$3 billion in the adult segment and the balance in the infant segment.
Market projections forecast the growth in this market from the $8.5 billion today to $12 billion or so over the next several years, really driven by growth in the adult market, both here in the U.S., as well as outside the country. To that end, we are coming off about a month away, removed from our results from our first pivotal phase III study of VAX-31, our PCV, a 31-valent PCV in the adult population. The data exceeded our own expectations, and we are thrilled to have the profile that we see with this vaccine. I know we will get into that. That study is the anchor for our phase III program of VAX-31 in adults to ultimately enable a BLA submission.
The rest of the program is comprised of the OPUS 2 and OPUS 3 studies, for which we expect data in the first half of next year, as well as a manufacturing consistency study, all to enable a BLA submission, for which we are guiding in the first half of 2028. In parallel with the clinical and manufacturing activities over the next several quarters to enable that submission, beginning to prepare for a commercial launch in this large and growing market. The infant segment is today larger. That is likely to ultimately equalize over time based on the growth in the adult market and our forecast. We have a 31-valent infant program underway where we have completed enrollment and expecting data from that phase II study by the end of the first half of next year. We can talk if we get into it about our unblinding and disclosure strategy.
Those adult and infant programs are really what anchors this company, and couldn't be more thrilled with the adult data and looking forward with high anticipations for the upcoming infant data readout. I'll cover one other aspect of our pipeline before we get into Q&A. We also have in the clinic our VAX-A1 program to prevent Group A Strep.
This is a program for which there's also an adult and infant opportunity, and we just announced last week we have advanced to the stage 2 portion of a phase I study in adults, the primary purpose of which is to explore the safety and tolerability of the vaccine, but ultimately to gather a dataset that will enable us to move into the school-aged children population in a phase II study where we believe we can demonstrate it with a reasonably sized study, efficacy study, whether we see the efficacy responses to further advance the program. Super excited to be here today. We did, on the heels of our readout last month, consummate a billion-dollar financing comprised of equity and convert. We now have pro forma for that financing, about $3.4 billion on the balance sheet as of the end of September.
Well-financed to advance all of our programs forward, and importantly with this financing, to fully fund the expected launch of VAX-31 in adults.
Great. Maybe we can just talk about the OPUS 1 top-line results. Robust data, but I'll leave it for you guys to kind of remind us how strong those data were.
Yeah. For me, they exceeded my expectations. I think the results speak for themselves. According to our protocol, we didn't miss on any of the primary endpoints. We went 11 for 11 for the serotypes that were in PCV20 and PCV21 in VAX-31. We went nine for nine for the ones in 20 and our 31, and we went eight for eight for the ones in CAPVAXIVE and that were in our vaccine, as well as meeting the superiority for the three that are in neither, plus cross-reactive 20B. Overall, we also had a number of results that were statistically greater. While that's not going to be as clinically relevant, it's good to see that the immunogenicity was sustained or improved in these overall results.
Great. So, maybe just in terms of some of the FDA's kind of thresholds, can you just remind us a little bit of the kind of more stringent threshold, what that means, and honestly, what it means for incremental potential competitors.
Yeah. So, the FDA has been watching each subsequent time that a new vaccine has been approved, from seven to 13 to 15 to 20, and so forth. What has happened because of carrier suppression, immunogenicity has decreased for all of the serotypes on average. So, it wasn't just one or two that were lower on average, 20, 25% decrease each time. Well, they're saying, okay, they're calling this immunologic creep. So they're saying, "Okay, we understand that there's a trade-off. We're getting greater breadth of coverage, more contemporary circulating disease, but we don't want to continue to sacrifice immunogenicity." So, the historical endpoint of 0.5 has been used. The FDA has said, "We want to see something a little bit more stringent because we've already seen some of this immunologic creep." Now, they asked us to accept that. We looked at our phase II data.
We felt that we have very strong immunogenicity, so we were okay with moving forward, and obviously, you can see what the results look like. So essentially, we met their standard. We don't see the immunologic creep that others have seen, and in fact, like I said, some have been even higher statistically than previously.
Yeah, I would just add to what Jim said. I mean, I think the combination of the improvement overall in immune responses with this new standard, to your question, Seamus Fernandez, will make it only that much more difficult for future potential broader valent vaccines to meet the required hurdles for approval.
Great. Maybe just to, before we get into more of the specifics around moving through the BLA, can you just remind us how much incremental coverage is being achieved with 31, whether it be versus PREVNAR 20 or CAPVAXIVE? Also, what are we learning along the way commercially that could be a limitation relative to missing kind of seven of the key serotypes?
Well, I'll let you cover the commercial.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
